RegenXBio (RGNX) AI Stock Analysis

• Market Cap: $491.07M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.27
• Revenue Growth: 80.70%
• EPS Growth: 46.66%
• Country: US
• Employees: 353
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): 0.12
• Shares Outstanding: 50,160,350
• 10 Day Avg. Volume: 1,515,995
• 30 Day Avg. Volume: 1,199,640
• PEG Ratio: -0.21
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $31.73
• Price Target Upside: 217.30% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

RegenXBio's overall score reflects a challenging financial position with ongoing losses and valuation concerns. However, strong clinical progress, strategic partnerships, and positive technical indicators provide optimism for future growth. Recent corporate events, such as the royalty monetization deal, further bolster the company's financial outlook.

Positive Factors

Clinical Trials

The AFFINITY DUCHENNE study of RGX-202 in Duchenne patients is progressing well, with over half of the 30 patients already enrolled.

Funding and Financials

The company received $150M upfront, which is expected to fund operations into early 2027.

Regulatory Progress

The FDA has accepted the Biologics License Application for RGX-121 with a Priority Review, indicating the importance and potential impact of the treatment.

Negative Factors

Regulatory Challenges

An accelerated approval pathway for RGX-202 for DMD may be viewed by some as having somewhat lower probability of success currently.

Safety and Risks

Safety will be closely scrutinized following a patient death from acute liver failure linked to a competitor's treatment, highlighting the need for ongoing monitoring.

RegenXBio Business Overview & Revenue Model

Company Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

How the Company Makes Money

RegenXBio generates revenue primarily through licensing agreements and collaborations related to its NAV Technology Platform. The company licenses its technology to other pharmaceutical and biotechnology companies, which in turn develop and commercialize gene therapy products. RegenXBio receives upfront payments, milestone payments, and royalties on sales of products developed using its platform. Additionally, the company engages in strategic partnerships and collaborations to co-develop therapies, sharing both the costs and profits. These partnerships often provide funding for research and development, contributing significantly to RegenXBio's earnings.

RegenXBio Financial Statement Overview

Summary

RegenXBio faces significant financial challenges with declining revenues and ongoing losses. Although the balance sheet shows moderate leverage, diminishing equity and assets, along with negative cash flow trends, highlight liquidity concerns.

Income Statement

RegenXBio has experienced declining revenue over recent years, notably a significant drop from 2021 to 2022, contributing to negative growth rates. The company has been operating at a loss, with negative EBIT and net income margins, indicating challenges in achieving profitability. Gross profit margins remain positive but declining revenue impacts overall performance.

Balance Sheet

The company maintains a manageable debt-to-equity ratio, indicating moderate leverage. However, stockholders' equity has been decreasing, reflecting potential financial strain. The equity ratio suggests a reasonable level of equity financing, yet decreasing total assets and equity pose concerns about long-term stability.

Cash Flow

RegenXBio's operating cash flow has been consistently negative, and free cash flow has also been negative, indicating cash flow challenges. The free cash flow to net income ratio reflects insufficient cash flow generation to cover losses, suggesting potential liquidity issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
83.33M	90.24M	112.72M	470.35M	154.57M
	Gross Profit
49.76M	53.03M	58.18M	418.51M	118.85M
	EBIT
-233.35M	-268.13M	-262.88M	159.98M	-119.23M
	EBITDA
-198.23M	-239.46M	-244.24M	169.54M	-96.83M
	Net Income Common Stockholders
-227.10M	-263.49M	-280.32M	127.84M	-111.25M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
234.69M	275.26M	364.64M	457.44M	475.74M
	Total Assets
465.99M	573.97M	833.27M	1.11B	708.16M
	Total Debt
82.03M	89.29M	94.80M	86.68M	72.65M
	Net Debt
24.51M	54.77M	-2.15M	-258.53M	-265.77M
	Total Liabilities
206.34M	262.23M	317.07M	349.61M	330.41M
	Stockholders Equity
259.65M	311.74M	516.20M	764.30M	377.75M
Cash Flow		Free Cash Flow
-175.56M	-228.37M	-238.21M	134.70M	-80.93M
	Operating Cash Flow
-173.13M	-218.41M	-207.49M	218.88M	-54.06M
	Investing Cash Flow
103.45M	190.94M	-11.93M	-406.64M	122.76M
	Financing Cash Flow
92.68M	-34.97M	-28.84M	195.25M	200.21M

RegenXBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGNX, the sentiment is Positive. The current price of 10 is above the 20-day moving average (MA) of 8.85, above the 50-day MA of 7.71, and above the 200-day MA of 9.04, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 64.71 is Neutral, neither overbought nor oversold. The STOCH value of 88.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGNX.

RegenXBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RGNX	62 Neutral	$491.07M	―	-47.44%	―	80.70%	46.66%
AMLX	57 Neutral	$477.80M	―	-83.24%	―	-100.32%	-197.69%
Sector *	52 Neutral	$5.19B	3.04	-44.20%	2.82%	16.59%	-0.39%
IVA	50 Neutral	$434.95M	―	344.74%	―	-47.32%	-26.67%
TSHA	50 Neutral	$598.91M	―	-159.34%	―	-48.97%	69.32%
VERV	48 Neutral	$389.56M	―	-34.26%	―	271.44%	26.65%
ERAS	34 Underperform	$348.44M	―	-45.82%	―	―	10.38%

RegenXBio Corporate Events

RegenXBio Secures $250M Royalty Monetization Deal

On May 16, 2025, REGENXBIO Inc. announced a strategic royalty monetization agreement with HealthCare Royalty Management, LLC, securing up to $250 million in non-dilutive funding through a limited recourse royalty bond. This agreement provides immediate capital of $150 million, extending the company’s cash runway into early 2027 and supporting its late-stage gene therapy programs. The deal allows REGENXBIO to leverage anticipated royalties from products like ZOLGENSMA® and potential future milestones, positioning the company to accelerate commercial preparations and maintain its leadership in gene therapy.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.

Spark’s Take on RGNX Stock

According to Spark, TipRanks’ AI Analyst, RGNX is a Neutral.

RegenXBio’s overall score reflects a challenging financial position due to persistent losses and valuation concerns. However, strong clinical progress, strategic partnerships, and a robust cash position from recent earnings call data point to potential future growth. Technical indicators suggest cautious optimism, despite current volatility.

To see Spark’s full report on RGNX stock, click here.

RegenXBio Partners with Nippon Shinyaku for Gene Therapies

On March 4, 2025, REGENXBIO Inc. announced the closing of a strategic partnership with Nippon Shinyaku to develop and commercialize gene therapies RGX-121 and RGX-111 for Mucopolysaccharidosis II and I, respectively, in the United States and Asia. This collaboration is expected to enhance REGENXBIO’s ability to progress its programs, potentially leading to transformative treatments for patients with these rare diseases. RGX-121, anticipated to be the first gene therapy for MPS II, may receive FDA approval by late 2025, highlighting the partnership’s potential impact on the company’s operations and industry positioning.